[PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section provides the company's unaudited financial statements, management's operational analysis, market risk disclosures, and internal control assessments [Item 1. Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) The unaudited financial statements for the period ended June 30, 2022, show a slight decrease in revenue and a significant increase in net loss compared to the prior year, with a decline in cash and total assets Condensed Consolidated Balance Sheets As of June 30, 2022, the company's total assets decreased to **$1.002 billion** from **$1.019 billion** at year-end 2021, primarily due to a significant reduction in cash and cash equivalents, while total liabilities increased to **$218.1 million**, leading to a decrease in total stockholders' equity to **$783.5 million** Balance Sheet Items (in millions) | Balance Sheet Items | June 30, 2022 (Unaudited) | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $274.2 | $587.4 | | Marketable securities | $225.5 | $0 | | Total current assets | $666.2 | $747.6 | | Total assets | $1,001.6 | $1,018.8 | | **Liabilities & Equity** | | | | Total current liabilities | $117.9 | $110.4 | | Total liabilities | $218.1 | $201.3 | | Total stockholders' equity | $783.5 | $817.6 | Condensed Consolidated Statements of Operations For the second quarter of 2022, revenue was nearly flat at **$114.6 million** compared to **$115.8 million** in Q2 2021, but a sharp increase in cost of revenue and operating expenses led to a significantly wider net loss of **$64.5 million**, compared to a net loss of **$11.1 million** in the prior-year period Statements of Operations (in millions, except per share data) | Metric | Q2 2022 | Q2 2021 | Six Months 2022 | Six Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $114.6 | $115.8 | $229.1 | $221.7 | | Gross Profit | $86.9 | $110.9 | $175.9 | $199.7 | | Loss from Operations | ($63.1) | ($10.3) | ($104.9) | ($20.5) | | Net Loss | ($64.5) | ($11.1) | ($106.9) | ($22.6) | | Net Loss Per Share | ($0.57) | ($0.10) | ($0.94) | ($0.21) | Condensed Consolidated Statements of Cash Flows For the six months ended June 30, 2022, net cash used in operating activities was **$37.8 million**, a significant increase from **$1.0 million** in the same period of 2021, with net cash used in investing activities surging to **$285.1 million** Statements of Cash Flows (in millions) | Cash Flow Activity | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($37.8) | ($1.0) | | Net cash used in investing activities | ($285.1) | ($58.9) | | Net cash provided by financing activities | $8.8 | $19.7 | | **Net decrease in cash** | **($314.3)** | **($39.9)** | Notes to Condensed Consolidated Financial Statements The notes provide details on accounting policies, revenue breakdown, ongoing litigation, and a significant subsequent event, including a workforce reduction and patent infringement lawsuits Revenue by Source (in millions) | Revenue by Source | Q2 2022 | Q2 2021 | Six Months 2022 | Six Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Instruments | $14.7 | $16.9 | $29.2 | $28.0 | | Consumables | $97.9 | $97.1 | $195.9 | $190.2 | | Services | $1.9 | $1.8 | $4.1 | $3.4 | | **Total revenue** | **$114.6** | **$115.8** | **$229.1** | **$221.7** | Revenue by Geography (in millions) | Revenue by Geography | Q2 2022 | Q2 2021 | | :--- | :--- | :--- | | United States | $69.4 | $64.0 | | Europe, Middle East and Africa | $25.6 | $28.8 | | China | $9.1 | $12.9 | | Asia-Pacific (excluding China) | $9.0 | $8.4 | | North America (excluding United States) | $1.5 | $1.8 | - On August 3, 2022, the company committed to a reduction in force affecting approximately **8% of its global workforce**, estimating severance costs between **$5 million and $6 million** to be recognized in Q3 2022[77](index=77&type=chunk) - The company is involved in ongoing patent infringement litigation, having filed suits against Nanostring Technologies, Inc. and Vizgen, Inc.[64](index=64&type=chunk)[65](index=65&type=chunk)[68](index=68&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the **1% YoY revenue decrease** in Q2 2022 to challenges including COVID-19 lockdowns in China, logistics issues, and execution challenges, while gross margin declined due to a one-time royalty reversal and operating expenses rose significantly - Q2 2022 revenue decreased **1% YoY**, impacted by COVID-19 lockdowns in China, logistics issues, and unfavorable currency fluctuations[88](index=88&type=chunk)[89](index=89&type=chunk) - Gross margin for Q2 2022 fell to **76%** from **96%** in Q2 2021, largely driven by a one-time reversal of **$14.7 million** in accrued royalties in the prior-year period[91](index=91&type=chunk) - Operating expenses increased **24%** in Q2 2022 compared to Q2 2021, with R&D expenses rising **32%** and SG&A expenses rising **15%**, primarily due to higher personnel-related costs, including stock-based compensation[94](index=94&type=chunk)[96](index=96&type=chunk)[100](index=100&type=chunk) - As of June 30, 2022, the company had **$274.2 million** in cash and cash equivalents and **$225.5 million** in marketable securities, which management believes is sufficient to meet cash needs for at least the next 12 months[109](index=109&type=chunk)[112](index=112&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's primary market risk exposure relates to interest rate fluctuations impacting its **$225.5 million** portfolio of marketable securities, where a hypothetical **100 basis-point (1%)** change would affect its fair value by approximately **$2.3 million** - The company's main market risk is interest rate risk associated with its **$225.5 million** in marketable securities[124](index=124&type=chunk)[125](index=125&type=chunk) - A hypothetical **100 basis-point** increase or decrease in interest rates would impact the fair value of the investment portfolio by approximately **$2.3 million**[125](index=125&type=chunk) [Item 4. Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2022, with no material changes in internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2022[126](index=126&type=chunk) - No changes occurred in the company's internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, these controls[127](index=127&type=chunk) [PART II. OTHER INFORMATION](index=28&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers legal proceedings, updates on risk factors, a list of exhibits, and the official executive signatures [Item 1. Legal Proceedings](index=28&type=section&id=Item%201.%20Legal%20Proceedings) The company is actively engaged in intellectual property litigation, having filed multiple patent infringement lawsuits against Nanostring Technologies, Inc. and Vizgen, Inc. concerning their respective products - The company has filed two separate lawsuits in the U.S. against Nanostring Technologies, Inc. alleging patent infringement by Nanostring's GeoMx and CosMx products, with trials scheduled for August 2023 and June 2024, respectively[131](index=131&type=chunk)[132](index=132&type=chunk) - A lawsuit was filed in Germany against Nanostring in March 2022, alleging infringement by the CosMx product, with a hearing scheduled for March 2023[133](index=133&type=chunk) - In May 2022, the company sued Vizgen, Inc. in the U.S., alleging that its MERSCOPE Platform infringes on several of the company's patents[134](index=134&type=chunk) [Item 1A. Risk Factors](index=28&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the company's risk factors from those previously disclosed in its Annual Report on Form 10-K - The company reports no material changes to its risk factors from those disclosed in its most recent Annual Report[136](index=136&type=chunk) [Item 6. Exhibits](index=29&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the company's certificate of incorporation, bylaws, and certifications by the CEO and CFO as required by the Sarbanes-Oxley Act - The exhibits filed with this report include certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[137](index=137&type=chunk) [Signatures](index=30&type=section&id=Signatures) The report is duly signed by Serge Saxonov, Chief Executive Officer, and Justin J. McAnear, Chief Financial Officer, on August 8, 2022

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $114.5 million, an 8% increase year-over-year from $105.8 million in Q1 2021 [53] - Consumables revenue was $98 million, up 5% year-over-year, while instrument revenue increased by 30% to $14.4 million, and service revenue rose by 31% to $2.1 million [53] - Gross profit for Q1 was $89 million, with a gross margin of 78%, down from 84% in the prior year, primarily due to changes in product mix and increased costs [59] - Operating loss for Q1 was $41.7 million, compared to a loss of $10.2 million in Q1 2021, driven by increased personnel-related expenses [61] - Net loss for the period was $42.4 million, compared to a net loss of $11.6 million in the first quarter of 2021 [62] Business Line Data and Key Metrics Changes - Strong demand for Chromium instruments was noted, particularly for the Chromium X Series, which is driving instrument demand and customer upgrades [11][12] - High throughput kits showed robust growth, with customers increasingly adopting HD kits for larger studies [13] - Multiomics products are among the fastest-growing, with broad adoption across various applications [15] - Demand for Visium products remained solid, with Visium cited in more publications than any other spatial biology tool [16][17] Market Data and Key Metrics Changes - Revenue for the Americas was $59.7 million, a 15% increase year-over-year, while EMEA revenue was $20.5 million, up 7% [54] - APAC revenue was $34.3 million, consistent with the prior year, but impacted by COVID-driven lockdowns in China [54][56] - The company expects Q2 revenue to be adversely affected by ongoing lockdowns in China, which are anticipated to normalize in the back half of the year [63][75] Company Strategy and Development Direction - The company is focused on three key areas for growth: new product pipeline, scaling the commercial organization, and strengthening operational capabilities [18] - Upcoming product launches include the fixed RNA profiling kit and the nuclear isolation kit, aimed at enhancing single-cell analysis capabilities [22][24] - The company aims to drive broad adoption of its platforms and remove bottlenecks in workflows to facilitate larger-scale studies [21][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth potential despite near-term headwinds, emphasizing the importance of single-cell analysis in biological research [10][66] - The operating environment is expected to improve, with strong customer enthusiasm for the product portfolio and pipeline [64] - The company anticipates a revenue split of approximately 40% in the first half and 60% in the second half of 2022, with growth accelerating in the latter half [64] Other Important Information - The company is investing in expanding its manufacturing capabilities and managing supply chain challenges [47][50] - A significant leadership transition is underway with the departure of the Chief Commercial Officer, but the company remains focused on maintaining momentum in its commercial strategy [45][46] Q&A Session Summary Question: Update on Chromium upgrade cycle and utilization trends - Management indicated that the upgrade cycle is in early stages, with increased interest across the customer base, particularly for the Chromium X Series [71] Question: Expectations for recovery in China post-lockdowns - The company expects normalization in the back half of the year, with significant revenue impact from the Shanghai area [75] Question: Insights on new product impacts and revenue guidance - Management noted that while new product launches typically do not have immediate revenue impact, multiple launches throughout the year are expected to support acceleration in Q3 and Q4 [79] Question: Details on the fixed RNA profiling kit and its market appeal - The fixed RNA profiling kit is expected to drive significant interest and upgrades among customers, particularly in the context of high throughput [81][102] Question: Clarification on the impact of cold chain logistics issues in Europe - The company faced a complex issue with temperature-controlled shipments, leading to sporadic product spoilage, but has implemented safeguards to prevent future occurrences [96]

For the quarterly period ended March 31, 2022 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of R ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Registrant as Specif ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2021 Earnings Conference Call February 16, 2022 4:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Conference Call Participants Tycho Peterson - JPMorgan Derik De Bruin - Bank of America Dan Brennan - Cowen Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Dan Arias - Stifel Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Hello, good afternoon, and welcome to the 10x ...

Mastering Biology to Advance Human Health Serge Saxonov, CEO and Co-founder GENOMICS © 10X GENOMICS, INC. 2022. 1 Disclaimer Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts may be f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR 10x Genomics, Inc. (Exact Name of Re ...

10x Genomics, Inc. (NASDAQ:TXG) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen & Company Tycho Peterson - JP Morgan Tejas Savant - Morgan Stanley Mike Ryskin - Bank of America David Westenberg - Guggenheim Securities Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Matt Lar ...

Company Overview - 10x Genomics has over 2,400 installed instruments[6] - The company's consumable pull-through is over $150,000[6] - 10x Genomics holds over 1,100 patents and applications[6] - There are over 2,500 publications referencing 10x Genomics' technology[6] - Approximately 50% of sales are outside the US[15] Product Platforms and Market Opportunity - The company operates across three product platforms: Chromium Single Cell, Visium Spatial, and In Situ[26] - 10x Genomics addresses a global life science research tools market estimated at $15 billion[32, 33] - The company sees a downstream clinical applications market opportunity for In Situ analysis of $10 billion[35, 36] New Product Initiatives - The company launched the CellPlex Kit in Q1 2021, reducing all-in cost by approximately 60%[41, 56] - The Low Throughput Kit launched in Q2 2021, reducing startup cost by over 60%[44, 56] - Visium for FFPE is coming in Q2 2021, solving the challenge of FFPE samples[61]